同種細胞療法市場：タイプ、用途、最終用途別-2025-2030年の世界予測

同種細胞療法市場は、2023年に20億4,000万米ドルと評価され、2024年には23億1,000万米ドルに達すると予測され、CAGR 13.90％で成長し、2030年には50億8,000万米ドルに達すると予測されています。

同種細胞療法では、様々な疾患や病状を治療するためにドナーからの細胞を使用することが含まれ、患者自身の細胞を利用する自己細胞療法とは一線を画しています。その必要性は、治療と標準化された細胞製品を即座に利用できる可能性に由来し、従来の方法では治療不可能なことが多いがんや遺伝性疾患などの重篤な疾患に対処します。臨床的には、この療法は血液学、腫瘍学、心臓学、再生医療に応用されており、移植と組織再生が主な最終用途分野です。主な成長促進要因としては、慢性疾患の有病率の上昇、研究開発への投資の増加、細胞ベース技術の進歩などが挙げられます。希少疾患への応用拡大、商業規模での製造改善、市場参入を促進する強固な規制枠組みの開発などに機会があります。このような機会を捉えるための調査には、バイオ医薬品企業、研究機関、政府機関の間の協力関係を促進し、開発と規制のプロセスを合理化することが含まれます。しかし、治療費の高さ、製造の複雑さ、免疫拒絶反応の可能性、細胞の調達や操作にまつわる倫理的懸念など、実質的な限界も存在し、市場の成長を阻害する可能性があります。課題としては、規制上のハードル、厳格な品質管理措置、移植における適合性の確保などが挙げられます。それでも、遺伝子編集技術、凍結保存技術の強化、免疫反応を抑えるための万能ドナー細胞株といった分野では、技術革新の可能性が広がっています。さらに、より費用対効果が高く拡張可能な製造ソリューションの開発は、市場浸透を大きく後押しする可能性があります。この市場の特徴は、急速な技術進歩、競合他社との競争、臨床的有効性と安全性への強いこだわりです。全体として、市場での成功への道には、戦略的イノベーション、コラボレーション、倫理的・規制的課題を克服するための積極的アプローチが必要です。

市場力学：急速に進化する同種細胞療法市場の主要市場インサイトを公開

同種細胞療法市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がん、自己免疫疾患、心血管疾患の増加
  • 好意的な政府政策と細胞ベースの治療研究への資金提供の増加
• 市場抑制要因
  • 同種細胞療法の開発と投与に関する複雑な規制環境
• 市場機会
  • 個別化同種細胞療法ソリューションの開発
  • 神経変性疾患や心疾患における新たな治療法の開拓
• 市場の課題
  • 免疫拒絶反応と適合性の問題

ポーターのファイブフォース：同種細胞療法市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：同種細胞療法市場における外部からの影響の把握

外部マクロ環境要因は、同種細胞療法市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析同種細胞療法市場における競合情勢の把握

同種細胞療法市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス同種細胞療法市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、同種細胞療法市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨同種細胞療法市場における成功への道筋を描く

同種細胞療法市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん、自己免疫疾患、心血管疾患の発生率の増加
    • 細胞ベースの治療法の調査に対する政府の好ましい政策と資金の増加
  • 抑制要因
    • 同種細胞療法の開発と管理に関する複雑な規制環境
  • 機会
    • パーソナライズされた同種細胞療法ソリューションの開発
    • 神経変性疾患および心臓疾患における新たな治療法の探究
  • 課題
    • 免疫拒絶と適合性の問題
• 市場セグメンテーション分析
  • タイプ：抗炎症および免疫調節特性による間葉系幹細胞療法の採用増加
  • 応用：臓器移植の治療と改善における同種細胞療法の役割を革新する
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 同種細胞療法市場：タイプ別

• キメラ抗原受容体T細胞療法
• 造血幹細胞移植
• 人工多能性幹細胞療法
• 間葉系幹細胞療法

第7章 同種細胞療法市場：用途別

• 血液疾患
• 腫瘍学
• 再生医療
• 固形臓器移植

第8章 同種細胞療法市場：最終用途別

• バイオテクノロジーおよび製薬会社
• 病院・クリニック
• 調査機関

第9章 南北アメリカの同種細胞療法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の同種細胞療法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの同種細胞療法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ゲティンゲとセルレブの戦略的提携で製造業に革命を起こす
  • StemCyteの画期的な臍帯血由来細胞療法への世界のアクセスを促進する先駆的な契約
  • FDAが血液がん治療の画期的な進歩としてガミダセル社のOmisirge療法を承認
• 戦略分析と提言

企業一覧

• Abeona Therapeutics Inc.
• AlloSource
• Anterogen.Co., Ltd.
• Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies
• Athersys Inc.
• Biorestorative Therapies Inc.
• Biosolution Co., Ltd.
• Bloodworks Northwest
• Brainstorm Cell Limited
• Caribou Biosciences
• Fate Therapeutics
• Gamida Cell
• Hope Biosciences
• JCR Pharmaceuticals Co., Ltd.
• Mallinckrodt Pharmaceuticals
• MEDIPOST Co., Ltd.
• Mesoblast Ltd.
• NuVasive Inc. by Globus Medical
• RTI Surgical
• Smith+Nephew PLC
• Stempeutics Research Pvt. Ltd.
• Sumitomo Pharma Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Tego Science Inc.
• ViaCyte Inc. by Vertex Pharmaceuticals

LIST OF FIGURES

• FIGURE 1. ALLOGENEIC CELL THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. ALLOGENEIC CELL THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ALLOGENEIC CELL THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ALLOGENEIC CELL THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY MESENCHYMAL STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY SOLID ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ALLOGENEIC CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. CANADA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. CHINA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. ITALY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. POLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. QATAR ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM ALLOGENEIC CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 148. ALLOGENEIC CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. ALLOGENEIC CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Allogeneic Cell Therapy Market was valued at USD 2.04 billion in 2023, expected to reach USD 2.31 billion in 2024, and is projected to grow at a CAGR of 13.90%, to USD 5.08 billion by 2030.

Allogeneic cell therapy involves the use of cells from a donor to treat various diseases and medical conditions, making it distinct from autologous therapies that utilize a patient's own cells. Its necessity stems from the potential to provide immediate availability of treatment and standardized cell products, addressing severe diseases, such as cancers and genetic disorders, which are often untreatable by conventional means. Clinically, this therapy has found applications in hematology, oncology, cardiology, and regenerative medicine, with transplant and tissue regeneration being primary end-use areas. Key growth drivers include rising prevalence of chronic diseases, increasing investments in research and development, and advances in cell-based technologies. Opportunities lie in expanding applications to rare diseases, commercial-scale manufacturing improvements, and developing robust regulatory frameworks that expedite market access. Recommendations for seizing these opportunities include fostering collaborations between biopharmaceutical companies, research institutes, and governmental bodies to streamline development and regulatory processes. However, substantial limitations exist, such as the high cost of therapy, complexity of production, potential for immune rejection, and ethical concerns around cell sourcing and manipulation, which could impede market growth. Challenges include regulatory hurdles, stringent quality control measures, and ensuring compatibility in transplantation. Still, innovation potentials abound in areas such as gene-editing technologies, enhanced cryopreservation techniques, and universal donor cell lines to reduce immune responses. Furthermore, the development of more cost-effective and scalable manufacturing solutions can significantly boost market penetration. The market is characterized by rapid technological advancements, competitive tension, and a strong focus on clinical efficacy and safety. Overall, the path to market success requires strategic innovations, collaboration, and a proactive approach to overcoming ethical and regulatory challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Allogeneic Cell Therapy Market

The Allogeneic Cell Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing incidences of cancers, autoimmune diseases, and cardiovascular conditions
  • Favorable government policies and increased funding for research in cell-based therapies
• Market Restraints
  • Complex regulatory environment for development and administration of allogeneic cell therapies
• Market Opportunities
  • Development of personalized allogeneic cell therapy solutions
  • Exploration into the new treatment avenues in neurodegenerative diseases and cardiac diseases
• Market Challenges
  • Immune rejection and compatibility issues

Porter's Five Forces: A Strategic Tool for Navigating the Allogeneic Cell Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Allogeneic Cell Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Allogeneic Cell Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Allogeneic Cell Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Allogeneic Cell Therapy Market

A detailed market share analysis in the Allogeneic Cell Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Allogeneic Cell Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Allogeneic Cell Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Allogeneic Cell Therapy Market

A strategic analysis of the Allogeneic Cell Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Allogeneic Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., AlloSource, Anterogen.Co., Ltd., Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies, Athersys Inc., Biorestorative Therapies Inc., Biosolution Co., Ltd., Bloodworks Northwest, Brainstorm Cell Limited, Caribou Biosciences, Fate Therapeutics, Gamida Cell, Hope Biosciences, JCR Pharmaceuticals Co., Ltd., Mallinckrodt Pharmaceuticals, MEDIPOST Co., Ltd., Mesoblast Ltd., NuVasive Inc. by Globus Medical, RTI Surgical, Smith+Nephew PLC, Stempeutics Research Pvt. Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Tego Science Inc., and ViaCyte Inc. by Vertex Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Allogeneic Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Chimeric Antigen Receptor T Cell Therapy, Hematopoietic Stem Cell Transplantation, Induced Pluripotent Stem Cell Therapy, and Mesenchymal Stem Cell Therapy.
• Based on Application, market is studied across Hematological Disorders, Oncology, Regenerative Medicine, and Solid Organ Transplantation.
• Based on End-Use, market is studied across Biotechnology & Pharmaceutical Companies, Hospitals & Clinics, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidences of cancers, autoimmune diseases, and cardiovascular conditions
    • 5.1.1.2. Favorable government policies and increased funding for research in cell-based therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Complex regulatory environment for development and administration of allogeneic cell therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of personalized allogeneic cell therapy solutions
    • 5.1.3.2. Exploration into the new treatment avenues in neurodegenerative diseases and cardiac diseases
  • 5.1.4. Challenges
    • 5.1.4.1. Immune rejection and compatibility issues
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Growing adoption of mesenchymal stem cell therapy due to anti-inflammatory and immunomodulatory properties
  • 5.2.2. Application: Revolutionizing allogeneic cell therapy's role in treating and improving organ transplantation procedures
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Allogeneic Cell Therapy Market, by Type

• 6.1. Introduction
• 6.2. Chimeric Antigen Receptor T Cell Therapy
• 6.3. Hematopoietic Stem Cell Transplantation
• 6.4. Induced Pluripotent Stem Cell Therapy
• 6.5. Mesenchymal Stem Cell Therapy

7. Allogeneic Cell Therapy Market, by Application

• 7.1. Introduction
• 7.2. Hematological Disorders
• 7.3. Oncology
• 7.4. Regenerative Medicine
• 7.5. Solid Organ Transplantation

8. Allogeneic Cell Therapy Market, by End-Use

• 8.1. Introduction
• 8.2. Biotechnology & Pharmaceutical Companies
• 8.3. Hospitals & Clinics
• 8.4. Research Institutes

9. Americas Allogeneic Cell Therapy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Allogeneic Cell Therapy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Allogeneic Cell Therapy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Getinge's Strategic Partnership with CellRev to Revolutionize Allogeneic Cell Therapy Manufacturing
  • 12.3.2. StemCyte's Pioneering Agreement for Advancing Worldwide Access to Groundbreaking Cord Blood-Derived Cell Therapies
  • 12.3.3. FDA Approval of Gamida Cell's Omisirge Therapy as Transformative Leap in Hematological Cancer Treatment
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abeona Therapeutics Inc.
• 2. AlloSource
• 3. Anterogen.Co., Ltd.
• 4. Atara Biotherapeutics by FUJIFILM Diosynth Biotechnologies
• 5. Athersys Inc.
• 6. Biorestorative Therapies Inc.
• 7. Biosolution Co., Ltd.
• 8. Bloodworks Northwest
• 9. Brainstorm Cell Limited
• 10. Caribou Biosciences
• 11. Fate Therapeutics
• 12. Gamida Cell
• 13. Hope Biosciences
• 14. JCR Pharmaceuticals Co., Ltd.
• 15. Mallinckrodt Pharmaceuticals
• 16. MEDIPOST Co., Ltd.
• 17. Mesoblast Ltd.
• 18. NuVasive Inc. by Globus Medical
• 19. RTI Surgical
• 20. Smith+Nephew PLC
• 21. Stempeutics Research Pvt. Ltd.
• 22. Sumitomo Pharma Co., Ltd.
• 23. Takeda Pharmaceutical Company Limited
• 24. Tego Science Inc.
• 25. ViaCyte Inc. by Vertex Pharmaceuticals